Disulfiram
As of the edition of 20 October 2026, Disulfiram is a small molecule: marketed, first approved in 1949 (ES); acts on ALDH2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Small molecule
- Brand name
- Antabuse
- First approved
- 1 October 1949 (ES)
- Approvals on record
- 5 in 4 regions
- Holder of the most recent approval
- Stallergenes; 4 holders in all
- Registered trials
- 50, 10 stopped early
- Disease areas
- Cancer; Chemically induced; Mental health; Infections; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Disulfiram.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ALDH2 | Aldehyde dehydrogenase, mitochondrial | P05091 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 5 | 0 | 1 |
| Phase 1 | 14 | 3 | 4 | 5 |
| Phase 2 | 22 | 16 | 3 | 3 |
| Phase 3 | 2 | 2 | 0 | 0 |
| Phase 4 | 5 | 3 | 0 | 1 |
| All trials | 50 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Stallergenes | Applicant | 2010 to now |
| Teva | Acquired holder | 2011 to now |
| Pfizer | Earlier holder |